| GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE®) fusion protein immune cell engager technology platform. Co.'s TriKE® platform generate proprietary therapeutics designed to harness and improve the cancer killing abilities of a patient's own natural killer cells. Co. is using its TriKE® platform for immuno-oncology products that can treat a range of hematologic malignancies and solid tumors, as well as to develop therapeutics for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus. We show 9 historical shares outstanding datapoints in our coverage of GTBP's shares outstanding history.|
Understanding the changing numbers of GTBP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like GTBP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching GTBP by allowing them to research GTBP shares outstanding history
as well as any other stock in our coverage universe.